肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2010年
12期
822-824
,共3页
崔雨田%王艳峰%丁弋%苏文
崔雨田%王豔峰%丁弋%囌文
최우전%왕염봉%정익%소문
甲状腺肿瘤%甲状腺肿,结节性%T淋巴细胞,调节性
甲狀腺腫瘤%甲狀腺腫,結節性%T淋巴細胞,調節性
갑상선종류%갑상선종,결절성%T림파세포,조절성
Thyroid neoplasms%Goiter,nodular%T-lymphocytes,regulatory
目的 分析甲状腺肿瘤患者外周血CD+4 CDHi25 CDLo127调节性T细胞(Treg)比例及其变化规律,初步探讨甲状腺肿瘤免疫抑制机制,以及分化型甲状腺癌和结节性甲状腺肿发病机制之间可能存在的相关性.方法 采用流式细胞术联合标记CD4、CD25、CD127,检测43例初治分化型甲状腺癌患者(分化型甲状腺癌组)、132例初治结节性甲状腺肿患者(结节性甲状腺肿组)及153名健康者(健康对照组)的外周血T细胞各亚群和Treg的比例.结果 分化型甲状腺癌组及结节性甲状腺肿组患者CD+4 CDHi25 CDLo127 Treg比例分别为(6.48±1.49)%及(6.23±1.67)%,均高于健康对照组的(5.62±1.48)%,差异有统计学意义(P<0.05),而分化型甲状腺癌组及结节性甲状腺肿组之间,差异无统计学意义(P>0.05).结论 结节性甲状腺肿与分化型甲状腺癌患者外周血CD+4 CDHi25 CDLo127 Treg比例较健康者均显著升高,提示CD+4 CDHi25 CDLo127 Treg可能是甲状腺肿瘤患者免疫抑制的重要原因之一.
目的 分析甲狀腺腫瘤患者外週血CD+4 CDHi25 CDLo127調節性T細胞(Treg)比例及其變化規律,初步探討甲狀腺腫瘤免疫抑製機製,以及分化型甲狀腺癌和結節性甲狀腺腫髮病機製之間可能存在的相關性.方法 採用流式細胞術聯閤標記CD4、CD25、CD127,檢測43例初治分化型甲狀腺癌患者(分化型甲狀腺癌組)、132例初治結節性甲狀腺腫患者(結節性甲狀腺腫組)及153名健康者(健康對照組)的外週血T細胞各亞群和Treg的比例.結果 分化型甲狀腺癌組及結節性甲狀腺腫組患者CD+4 CDHi25 CDLo127 Treg比例分彆為(6.48±1.49)%及(6.23±1.67)%,均高于健康對照組的(5.62±1.48)%,差異有統計學意義(P<0.05),而分化型甲狀腺癌組及結節性甲狀腺腫組之間,差異無統計學意義(P>0.05).結論 結節性甲狀腺腫與分化型甲狀腺癌患者外週血CD+4 CDHi25 CDLo127 Treg比例較健康者均顯著升高,提示CD+4 CDHi25 CDLo127 Treg可能是甲狀腺腫瘤患者免疫抑製的重要原因之一.
목적 분석갑상선종류환자외주혈CD+4 CDHi25 CDLo127조절성T세포(Treg)비례급기변화규률,초보탐토갑상선종류면역억제궤제,이급분화형갑상선암화결절성갑상선종발병궤제지간가능존재적상관성.방법 채용류식세포술연합표기CD4、CD25、CD127,검측43례초치분화형갑상선암환자(분화형갑상선암조)、132례초치결절성갑상선종환자(결절성갑상선종조)급153명건강자(건강대조조)적외주혈T세포각아군화Treg적비례.결과 분화형갑상선암조급결절성갑상선종조환자CD+4 CDHi25 CDLo127 Treg비례분별위(6.48±1.49)%급(6.23±1.67)%,균고우건강대조조적(5.62±1.48)%,차이유통계학의의(P<0.05),이분화형갑상선암조급결절성갑상선종조지간,차이무통계학의의(P>0.05).결론 결절성갑상선종여분화형갑상선암환자외주혈CD+4 CDHi25 CDLo127 Treg비례교건강자균현저승고,제시CD+4 CDHi25 CDLo127 Treg가능시갑상선종류환자면역억제적중요원인지일.
Objective To analyze CD+4 CDHi25 CDLo127 regulatory T cells (Treg) in peripheral blood of patients with thyroid nodules and differentiated thyroid cancer and their change regularity, and to investigate the immunosuppression mechanism. Methods The peripheral blood was collected from 175 patients with thyroid nodules, including 43 patients with differentiated thyroid cancer and 132 patients with nodular goiter.By using monoclonal antibodies, the blood samples were evaluated with the flow cytomertry for lymphocyte subsets and Treg cells. Results The results showed the prevalence of the CD+4 CDHi25 CDLo127 Treg in differentiated thyroid cancer group [(6.48±1.49) %] and nodular goiter group [(6.23+1.67) %] was higher than those in the healthy group [(5.62±1.48) %], and the difference was significant(P < 0.005), but there was no significant difference between the nodular goiter group and differentiated thyroid cancer group (P >0.005).Conclusion It is concluded that the relative increase of CD+4 CDHi25 CDLo127 Treg in peripheral blood of patients with nodular goiter and differentiated thyroid cancer may be related to immunosuppression and tumor progression.
